138001 D-Amino Acid Oxidase Inhibitor II, CBIO - CAS 61977-29-5 - Calbiochem

138001
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Specifications Table

      Empirical FormulaCAS #
      C₇H₄ClNO₂ 61977-29-5

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      138001-50MG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service
          Contact Customer Service

          Glass bottle 50 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewA cell-permeable benzisoxazolone compound that potently inhibits D-amino acid oxidase (DAO/DAAO/DAMOX/OXDA) activity (IC50 = 90 and 150/188 nM against rat spinal cord and porcine kidney DAO, respectively) in a reversible and D-serine-competitive (Ki = 100 nM) manner. Upon co-administration, CBIO (30 mg/kg, p.o.) markedly prolongs the half-life of orally administered D-serine (30 mg/kg) in plasma, resulting in enhanced rat brain D-serine level (60% vs. 25% above basal, respectively, with vs. without CBIO). Direct intrathecal/spinal CBIO injection either before (ED50 =60 ng) or after (ED50 = 170 ng) subcutaneous formalin injection (50 µl 5% solution) greatly alleviates formalin-induced late phase tonic pain (Emax =67%), but not early phase acute nociception in rats in vivo.
          Catalogue Number138001
          Brand Family Calbiochem®
          Synonyms6-Chloro-1,2-benzisoxazol-3(2H)-one, 6-Chlorobenzo[d]isoxazol-3-ol, D-AAO Inhibitor II, CBIO
          References
          ReferencesGong, N., et al. 2011. J. Pharmacol. Exp. Ther. 336, 282.
          Ferraris, D., et al. 2008. J. Med. Chem. 51, 3357.
          Product Information
          CAS number61977-29-5
          FormOff-white powder
          Hill FormulaC₇H₄ClNO₂
          Chemical formulaC₇H₄ClNO₂
          Structure formula ImageStructure formula Image
          Applications
          Biological Information
          Purity≥97% by HPLC
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          R PhraseR: 36/37/38

          Irritating to eyes, respiratory system and skin.
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
          Toxicity Irritant
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          138001

          References

          Reference overview
          Gong, N., et al. 2011. J. Pharmacol. Exp. Ther. 336, 282.
          Ferraris, D., et al. 2008. J. Med. Chem. 51, 3357.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision24-October-2011 RFH
          Synonyms6-Chloro-1,2-benzisoxazol-3(2H)-one, 6-Chlorobenzo[d]isoxazol-3-ol, D-AAO Inhibitor II, CBIO
          DescriptionA cell-permeable benzisoxazolone compound that potently inhibits D-amino acid oxidase (DAO/DAAO/DAMOX/OXDA) activity (IC50 = 90 and 150/188 nM against rat spinal cord and porcine kidney DAO, respectively) in a reversible and D-serine-competitive (Ki = 100 nM) manner. Upon co-administration, CBIO (30 mg/kg, p.o.) markedly prolongs the half-life of orally administered D-serine (30 mg/kg) in plasma, resulting in enhanced rat brain D-serine level (60% vs. 25% above basal, respectively, with vs. without CBIO). Direct intrathecal/spinal CBIO injection either before (ED50 =60 ng) or after (ED50 = 170 ng) subcutaneous formalin injection (50 µl 5% solution) greatly alleviates formalin-induced late phase tonic pain (Emax =67%), but not early phase acute nociception in rats in vivo.
          FormOff-white powder
          Intert gas (Yes/No) Packaged under inert gas
          CAS number61977-29-5
          Chemical formulaC₇H₄ClNO₂
          Structure formulaStructure formula
          Purity≥97% by HPLC
          SolubilityDMSO (50 mg/ml). It is recommended to prepare a stock solution for 6 month use each time and store the unreconstituted material in solid form, protected from moisture and preferably under inert gas, for best long-term stability during storage.
          Storage +2°C to +8°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Toxicity Irritant
          ReferencesGong, N., et al. 2011. J. Pharmacol. Exp. Ther. 336, 282.
          Ferraris, D., et al. 2008. J. Med. Chem. 51, 3357.